Endocrine Abstracts

Tyrosine kinase inhibitors and other targeted treatments are revolutionizing the treatment of cancer. However multiple endocrine side effects of these treatments are emerging.Crizotinib, a multi-targeted small molecule tyrosine kinase inhibitor of ALK and c-met, has been approved by the FDA for the treatment of non small cell lung cancer (NSCLC) patients with a novel oncogenic gene fusion, EML4-ALK and its variants. Crizotinib is generally well tolerated...

Medullary Thyroid Cancer (MTC) is sporadic in approximately 75% whilst 25% of MTC occurs as hereditary forms due to RET mutations. Prognosis is relatively good with 10-year survival rates of 65%. However, many patients develop recurrent disease and imaging is critical to localise the site of recurrence. Eighty-eight MTC patients, attending the Royal Marsden Hospital NHS Trust were included in an analysis of overall survival. Median Follow-up duration was 7.5 years (IQR: 4.5&#1...